

## Weekly feature:

### Introducing our new-look COVID-19 Resource Centre

**Centre:**we've made the latest research and reviews on COVID-19 more accessible and easy to navigate. Use the new search function to explore all content from across the *Lancet* family of journals.

[Explore this Resource Centre](#)

## Online First:

[Corrections] Correction to Lancet Infect Dis 2020; published online March 25. [https://doi.org/10.1016/S1473-3099\(21\)00151-1](https://doi.org/10.1016/S1473-3099(21)00151-1)

Published: Wednesday, March 31, 2021 11:30 PM

Maharaj AS, Parker J, Hopkins JP, et al. The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada. *Lancet Infect Dis* 2021; published online March 25. [https://doi.org/10.1016/S1473-3099\(21\)00151-1](https://doi.org/10.1016/S1473-3099(21)00151-1)—This Comment had incorrect copyright information. This correction has been made to the online version as of March 31, 2021, and will be made to the printed version.

[Read more »](#)

[Comment] The interplay between COVID-19 restrictions and vaccination

Published: Wednesday, March 31, 2021 11:30 PM

An intervention is only as effective as the extent to which people are willing to adopt recommended measures. One obstacle to the success of COVID-19 interventions, especially in the USA, has been the politicisation of control measures, including the adoption of masks and physical distancing. Interplay between acceptance of non-pharmaceutical interventions and vaccination shapes local transmission dynamics. Despite the importance of human

behaviour to the epidemiological trajectory, the integration of these interdependent factors into COVID-19 vaccination models has rarely been done.

[Read more »](#)

[Articles] [Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study](#)

Published: Wednesday, March 31, 2021 11:30 PM

The most effective vaccination strategy for reducing mortality due to COVID-19 depends on the time course of the pandemic in the population. For later vaccination start dates, use of SARS-CoV-2 vaccines to interrupt transmission might prevent more deaths than prioritising vulnerable age groups.

[Read more »](#)

[Correspondence] [Post-disruption catch-up of child immunisation and health-care services in Bangladesh](#)

Published: Tuesday, March 30, 2021 11:30 PM

The COVID-19 pandemic has affected child immunisation service delivery and use across the globe.<sup>1–4</sup> Amid overwhelming reports of disrupted immunisation services during the early pandemic months, the Correspondence by Anna A Jarchow-MacDonald and colleagues<sup>5</sup> drew our interest. The authors reported on stable child immunisation services in the Lothian area of Scotland during the lockdown period and described attributable adaptations and strategies.

[Read more »](#)

[Comment] [Moxidectin: an ally to ivermectin for treating \*Strongyloides stercoralis\*?](#)

Published: Tuesday, March 30, 2021 11:30 PM

*Strongyloides stercoralis* infection has long been neglected by the scientific community, despite the threat it poses to the individual and collective health.<sup>1</sup> In 2020, WHO included this infection in its public health targets for 2030,<sup>2</sup> pointing out that control measures for strongyloidiasis are of paramount importance in endemic countries. This target might necessitate the massive use of ivermectin, the only drug, effective in a single dose, that can contribute to decisively decreasing the prevalence of this deadly parasite.

[Read more »](#)

[Articles] [Efficacy and safety of ascending doses of moxidectin against \*Strongyloides stercoralis\* infections in adults: a randomised, parallel-group,](#)

single-blinded, placebo-controlled, dose-ranging, phase 2a trial

Published: Tuesday, March 30, 2021 11:30 PM

4–12 mg of moxidectin showed promising tolerability and efficacy profiles in the treatment of *S stercoralis* infections in adults. Because 8 mg of moxidectin is used for the treatment of onchocerciasis and has been evaluated for other helminth infections, we recommend this dose for phase 2b and phase 3 trials of strongyloidiasis therapy.

[Read more »](#)

## CAS 42-21: Weekly Update | The Lancet Respiratory Medicine

Weekly Update

### Weekly feature:

**Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial**

[Read the Article](#)

### Online First:

[\[Spotlight\] I won't let cystic fibrosis stop me from living my best life](#)

Published: Wednesday, March 24, 2021 11:30 PM

In the year 2000, at 2 years old, I started showing symptoms of cystic fibrosis (CF); I initially had a heel prick test, but I was not

» [Online First](#)

» [Current issue](#)

» [About this journal](#)

diagnosed with CF until I had a blood test. The day I was diagnosed, my parents decided that I would have all the treatments I needed to keep me well, and they were determined that I would have a normal life and that CF would not define me.

[Read more »](#)

» [Register](#) to  
receive Table of  
Contents alerts

ADVERTISEMENT:

### [\[Comment\] Challenges and opportunities to end tuberculosis in the COVID-19 era](#)

Published: Wednesday, March 24, 2021 8:40 AM

On World Tuberculosis Day, 2020, we warned of the impending impact of COVID-19 on the tuberculosis pandemic. We also made a plea that the world must not forget tuberculosis while it focused on COVID-19.<sup>1</sup>

[Read more »](#)

### [\[Comment\] REPLACE and the role of riociguat in pulmonary arterial hypertension therapy](#)

Published: Wednesday, March 24, 2021 11:30 PM

Following completion of the randomised placebo-controlled study of riociguat for the treatment of inoperable or residual chronic thromboembolic pulmonary hypertension,<sup>1</sup> riociguat became the only vasodilator therapy approved by the US Food and Drug Administration to treat this difficult disease, and accordingly plays a substantive role in therapy for those with WHO Group 4 pulmonary hypertension. On the basis of the robust results of the Pulmonary Arterial Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 (PATENT-1) study,<sup>2</sup> in which 194 (44%) of 443 participants were on background therapy with an endothelin receptor antagonist, riociguat also received approval for the treatment of pulmonary arterial hypertension (PAH).

[Read more »](#)

[\[Articles\] Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension \(REPLACE\): a multicentre, open-label, randomised controlled trial](#)

Published: Wednesday, March 24, 2021 11:30 PM

Switching to riociguat from PDE5i treatment, both of which act via the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate pathway, could be a strategic option for treatment escalation in patients with PAH at intermediate risk of 1-year mortality.

[Read more »](#)

The best science for better lives

[Manage your mailing preferences](#) to choose which *Lancet* Update alerts you receive.

The Lancet | Elsevier Limited | The Boulevard, Langford Lane | Kidlington, Oxford | United Kingdom, OX5 1GB